E. Ohman J or Asset Management AB Acquires 2,100 Shares of Hologic, Inc. (NASDAQ:HOLX)

E. Ohman J or Asset Management AB increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 25.9% during the fourth quarter, HoldingsChannel reports. The firm owned 10,200 shares of the medical equipment provider’s stock after buying an additional 2,100 shares during the period. E. Ohman J or Asset Management AB’s holdings in Hologic were worth $735,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of HOLX. Wolff Wiese Magana LLC bought a new position in shares of Hologic during the third quarter valued at $25,000. General Partner Inc. bought a new position in Hologic in the fourth quarter valued at about $26,000. Groupama Asset Managment lifted its holdings in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 2,999 shares during the period. First Horizon Advisors Inc. lifted its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Finally, Cromwell Holdings LLC lifted its holdings in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares during the period. 94.73% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HOLX. Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Jefferies Financial Group began coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. UBS Group upped their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Eight analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Hologic has an average rating of “Moderate Buy” and an average price target of $88.92.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.88% of the stock is owned by corporate insiders.

Hologic Stock Performance

NASDAQ HOLX opened at $72.80 on Thursday. The stock has a market capitalization of $16.43 billion, a PE ratio of 21.86, a P/E/G ratio of 2.35 and a beta of 0.98. The business has a 50 day simple moving average of $72.91 and a two-hundred day simple moving average of $77.95. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a 1-year low of $68.61 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.